Trillium Therapeutics Inc (TRIL) is near the top in its industry group according to InvestorsObserver. TRIL gets an overall rating of 52. That means it scores higher than 52 percent of stocks. Trillium Therapeutics Inc gets a 64 rank in the Biotechnology industry. Biotechnology is number 79 out of 148 industries.

Click Here to get the full Stock Score Report on Trillium Therapeutics Inc (TRIL) Stock.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 52 means the stock is more attractive than 52 percent of stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Trillium Therapeutics Inc (TRIL) stock is higher by 14.56% while the S&P 500 has fallen -0.04% as of 9:59 AM on Friday, Dec 13. TRIL has risen $0.07 from the previous closing price of $0.48 on volume of 695,414 shares. Over the past year the S&P 500 has gained 19.49% while TRIL has fallen -68.93%. TRIL earned $2.58 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 0.21.

To see the top 5 stocks in Biotechnology click here.

Link:
Is Trillium Therapeutics Inc (TRIL) Stock a Good Buy in Biotechnology - InvestorsObserver